Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.1 Exhibit 3.1
- 3.3 Exhibit 3.3
- 4.1 Exhibit 4.1
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.20 Exhibit 10.20
- 21.1 Exhibit 21.1
- 21.2 Exhibit 21.2
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 23.3 Exhibit 23.3
- EX-FILING FEES Filing Fees Table
Associated filings
- 5 Dec 22 EFFECT Notice of effectiveness
- 2 Dec 22 424B3 Prospectus supplement
- 1 Dec 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 2 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 7 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
2 Sep 22 S-4 Registration of securities issued in business combination transactions
IRON similar filings
- 23 Nov 22 Registration of securities issued in business combination transactions (amended)
- 2 Nov 22 Registration of securities issued in business combination transactions (amended)
- 7 Oct 22 Registration of securities issued in business combination transactions (amended)
- 2 Sep 22 Registration of securities issued in business combination transactions
- 15 Jan 21 Registration of securities issued in business combination transactions (amended)
- 15 Jan 21 Registration of securities issued in business combination transactions (amended)
- 12 Jan 21 Registration of securities issued in business combination transactions (amended)
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 25, 2022, with respect to the consolidated financial statements of Disc Medicine, Inc. included in the Registration Statement (Form S-4) and related Proxy Statement/Prospectus of Gemini Therapeutics, Inc. for the registration of its common stock.
/s/ Ernst & Young LLP |
Boston, Massachusetts |
September 2, 2022 |